OMERACT 8 PsA Module Proposal Submitted by: Dafna Gladman and Philip Mease.

Slides:

Advertisements

Similar presentations

Responding to the Patient’s Voice: the importance of Patient Reported Outcomes Dr. Kirstie Haywood Senior Research Fellow RCN Research Institute, School.

Advertisements

Psoriatic Arthritis Emily Chang Morning Report August 14, 2009 August.

Participation Requirements for a Patient Representative.

Role of the Statistician and the Bioinformatics Scientist in Cancer Clinical Trials Larry Rubinstein, PhD Biometric Research Branch, NCI International.

Psoriatic Arthritis: Creating a Model for Cost- Effectiveness Analysis GRAPPA meeting San Antonio, TX October 15, 2004 Supported by Schering Participants:

Dr. Zhao TCM help Rheumatoid Arthritis. What is Rheumatoid Arthritis (RA)? RA is an autoimmune disorder inflammation of the lining of the joints. The body.

Guidelines Mission Statement “To develop guidelines, based upon the best scientific evidence, for the optimal treatment of patients with psoriatic arthritis.

Identifying Domains of Inquiry in Psoriatic Arthritis Dafna D. Gladman, Professor of Medicine, University of Toronto, Director, Psoriatic Arthritis Program.

First International Psoriatic Arthritis Working Group Meeting: 8/15-17/03 NYC Philip Mease MD.

What is the definition of remission in RA? American Rheumatism Association (ARA)¹ Five or more of the following criteria must be fulfilled for at least.

Measuring Signs and Symptoms in Rheumatoid Arthritis David R. Karp, MD, PhD Chief, Rheumatic Diseases UT Southwestern Medical Center David R. Karp, MD,

The Impact of IMMPACT Bob A. Rappaport, M.D. Director Division of Anesthesia, Analgesia and Rheumatology Products Center for Drug Evaluation and Research.

GRAPPA Guidelines for PsA: Considerations

GRAPPA Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Philip Mease MD.

GRAPPA Examples of Work Projects Philip Mease. Examples of GRAPPA Work Projects Classification and diagnosis of PsA (CASPAR) Evaluation of PsA composite.

An assessment tool for dactylitis Philip Helliwell.

Rehabilitation Teaching and Research Unit, Wellington School of Medicine and Health Sciences Outcome measures in psoriatic arthritis Preliminary identification.

PsA: Review of Available Assessment Instruments and Lessons from Trial Results Part II Christian Antoni Friedrich Alexander University Erlangen-Nürnberg.

AM Report 11/24/09 Amy Auerbach  Peak onset between 20 and 30 years  Form of spondyloarthritis (cause inflammation around site of ligament insertion.

OUTCOME MEASURES IN PsA: TISSUE ANALYSIS Oliver FitzGerald.

Group for Research and Assessment in Psoriasis and Psoriatic Artritis PGA/VAS Patient and Physician Perception of disease in Psoriatic Arthritis (3PPsA)

CLAIMS STRUCTURE FOR SLE Jeffrey Siegel, M.D. Arthritis Advisory Committee September 29, 2003.

Core Outcome Domains for Eczema – Results of a Delphi Consensus Project Introduction Eczema is a chronic, relapsing, inflammatory skin disorder that affects.

GRAPPA research committee Philip Helliwell. History Steering committee in March 2005 received an application for funds to support a research project No.

NSAIDs and Radiographic Progression in Ankylosing Spondylitis By Abd El-Samad El-Hewala Professor of Rheumatology and Rehabilitation Faculty of Medicine.

OMERACT 8 PsA Module Co-Chairs Dafna Gladman and Philip Mease Steering Committee Alice Gottlieb, Philip Helliwell, Arthur Kavanaugh, Gerry Krueger, Peter.

Psoriatic Arthritis Workshop OMERACT May 14 th, 2004 Steering Committee Dafna Gladman, Philip Mease, Gerald Krueger, Désirée van der Heijde, Christian.

CPTR Overview CPTR 2012 Workshop October 2-4, 2012.

EFFICACY OF SPA THERAPY IN RHEUMATOID ARTHRITIS-A RANDOMISED CONTROLLED CLINICAL STUDY Mine Karagülle Department of Medical Ecology and Hydroclimatology.

Assessment of enthesitis in psoriatic arthritis

OMERACT 8 PsA Module Co-Chairs Dafna Gladman and Philip Mease Steering Committee Alice Gottlieb, Oliver FitzGerald, Philip Helliwell, Arthur Kavanaugh,

Axial Spondyloarthritis (SpA): Representative Values of Sensitivity and Specificity for Several Tests with the Resulting LRs *LR+ = sensitivity/(1 – specificity);

Application of Imaging Modalities to Musculoskeletal Soft Tissues Modalities –Magnetic resonance. –Ultrasound. –Computed tomography (CT). –Positron emission.

Outcome measures for balneotherapy NATIONAL INSTITUTE OF RHEUMATOLOGY AND PHYSIOTHERAPY Budapest, Hungary Dr. LÁSZLÓ HODINKA Recommendations.

GRAPPA Meeting, Oct. 16, 2004 San Antonio, Texas Patient Global Question Alberto Cauli Rheumatology Division University of Cagliari, Italy Director Prof.

Group for Research and Assessment in Psoriasis and Psoriatic Artritis PGA/VAS Patient and Physician Perception of disease in Psoriatic Arthritis (3PPsA)

OMERACT Workshop Outcome Measures in Psoriatic Arthritis

Guideline Development Societal needs have driven guideline development to the forefront: – Aid physician education on new clinical information – Set research.

Outcome Measures in PsA Philip Mease MD Seattle, WA.

Psoriatic Arthritis Workshop Part 2 OMERACT May 15 th, 2004 Steering Committee Dafna Gladman, Philip Mease, Gerald Krueger, Désirée van der Heidje, Christian.

GRAPPA Guidelines for PsA: Considerations GRAPPA Guidelines Mission Statement: “To develop guidelines, based upon the best scientific evidence, for the.

GRAPPA Committee Reports and Outcome measures Dafna D. Gladman, MD, FRCPC Professor of Medicine, University of Toronto Director, PsA Program, University.

Psoriatic Arthritis Workshop OMERACT 7 Steering Committee Dafna Gladman, Philip Mease, Gerald Krueger, Désirée van der Heijde, Christian Antoni, Philip.

Improving Patient-Centered Outcomes in Bone Conduction Hearing Implants James Tysome PhD, FRCS (ORL-HNS) ENT Surgeon, Cambridge University Hospitals Ad.

Joachim Sieper, Désirée van der Heijde, Maxime Dougados, L Steve Brown,Frederic Lavie, Aileen L Pangan Ann Rheum Dis 2012;71: doi: /annrheumdis

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis R1 신가영 / Modulator Prof. 이연아 N Engl J Med 2015; 373: Philip J.

Training on the Modular Approach on the assessment and management of psoriatic arthritis (PsA) for dermatology units This PsA Assessment initiative is.

Psoriatic Arthritis.

Effective Management of Psoriatic Arthritis: Tailoring Treatments

Vibeke Strand, MD, MACR, Jasvinder A. Singh, MD, MPH

Part 1: Disease Activity Measures

What’s the Big Deal About Brain Atrophy and Neurodegeneration in RRMS?

IL-17 Inhibitors in the Management of Psoriatic Disease

Figure 2 Simplified EULAR and GRAPPA

Updated 2016 PsA Core Domain Set.

Differentiate the function: {image} .

Gait Sub study Anat Mirelman PhD.

Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR50, (B) CDAI LDA and (C) HAQ-DI

Clinical and patient-reported outcomes for patients randomised to CZP 200 mg Q2W and CZP 400 mg Q4W to week 96. Clinical and patient-reported outcomes.

What on earth is Spondyloarthritis

OR for baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by univariate analysis of observed data. OR for baseline predictors of MDA at weeks 12,

Box plot of HAQ-DI scores at baseline, week 96 and week 144 categorised by baseline PsA duration. Box plot of HAQ-DI scores at baseline, week 96 and week.

Representative ultrasound images of patients with SLE

Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR70, (B) CDAI REM and (C) SDAI REM. For tofacitinib 5 and 10 mg BID treatment.

Percentages of patients reporting improvements from baseline ≥minimum clinically important difference (MCID) and number needed to treat (NNT) in (A) patient-reported.

A. A. Percentages of patients with active dactylitis in ≥ 4 digits (fingers or toes) at baseline and Week 12. *p < versus baseline. Data are observed.

Achievement of MDA over 144 weeks in patients initially receiving adalimumab or placebo during the double-blind period. Achievement of MDA over 144 weeks.

(A) JIA-ACR30/50/70/90 response rates by visit in part 1.

MRI remission in the imaging set of patients from the RAPID-axSpA trial. MRI remission in the imaging set of patients from the RAPID-axSpA trial. Remission.

Psoriatic Arthritis.

Presentation transcript:

OMERACT 8 PsA Module Proposal Submitted by: Dafna Gladman and Philip Mease

OMERACT 7 PsA Workshop Domains in PsA final vote ItemScore Joint activity Patient Global all 3 components Pain assessment Physical function Skin disease Quality of Life Structural damage Acute Phase Reactant Axial involvement Participation Enthesitis Fatigue Dactylitis Physician Global Tissue histology MRI Morning Stiffness Damage joint count 99% 96% 76% 94% 91% 86% 78% 66% 64% 61% 60% 48% 41% 38% 34% 25% 20%

OMERACT 7 PsA Workshop Research Agenda Identify optimal joint count. Develop instrument for patient global to incorporate skin and joint question. Identify optimal Skin assessment. Develop tools to define structural damage. Develop instruments for Axial assessment. Develop a tool for the assessment of participation. Develop instruments for the assessment of Enthesitis. Develop tools for the assessment Dactylitis. Imaging modalities to assess inflammation and damage. Develop Composite responder indices. Differential tissue response to therapies. Study methods to evaluate Fatigue in PsA.

PsA Module OMERACT 8 Objectives : – 1) achieve consensus on the core set of domains to be assessed in PsA clinical trials and in longitudinal observational cohort studies, – 2) review and endorse outcome measures used to assess these domains based on evidence derived from clinical trials and – 3) set up a new research agenda to identify other assessment tools.

PsA Module OMERACT 8 Key domains of PsA for which updated trial data will be available: – 1) Joint assessment – 2) Spine disease – 3) Enthesitis and dactylitis – 4) Imaging modalities – 5) Histologic and immunohistochemical markers – 6) QOL/function/participation – 7) Skin

PsA Module OMERACT 8 Process – OMERACT filter Truth, discrimination, feasibility – Each committee to report progress to D. Gladman quarterly. – Review progress at EULAR and ACR 2005, Gene to Clinic Nov – GRAPPA meeting at OMERACT Need ~30 GRAPPA members to participate 18 of whom will be scribes – Proceedings to be published in J Rheum